Healius Limited · ASX:HLS
Healius — Investor Day (March 2025)
72 slides from Healius's investor day presentation, Mar 27, 2025
Slide 1: Healius Investor Day 2025
Healius Investor Day 2025 27 March 2025
Slide 2: Important Information: Forward-looking statements
Important Information: Forward-looking statements This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Healius Limited. Readers are cautioned not to pla
Slide 3: Presenting today
Presenting today Paul Anderson Chief Executive Officer & Managing Director Anthea Muir Arjun Narang Dr. Dora Papamakarios Group Executive Group Executive General Manager Customer & Commercial Operations Genomic Diagnostics Prasad Arav Stephen McIntyre Steve Humphries Group Executive Chief Executive
Slide 4: Agenda
Agenda 1 Introduction & CEO Observations Paul Anderson 2 Delivering our Pathology Strategy Paul Anderson a Pillar 1: Customer Service Anthea Muir b Pillar 2: Laboratory Modernisation Arjun Narang c Pillar 3: Emerging Diagnostics Dr. Dora Papamakarios d Technology Enablers Prasad Arav 3 Agilex Biolab
Slide 5: Introduction and Corporate Update
Introduction and Corporate Update • Over the past 12 months we have: – Refinanced and reduced our debt facilities in April 2024 – Completed our Operating & Strategic Review culminating in the sale of Lumus Imaging for $965m – Developed and implemented a new Pathology Strategy & National Operating Mo
Slide 6: CEO Observations
CEO Observations Strong momentum to execute our strategy and achieve T27 plan Positives Focus areas being worked on Strategic clarity – major building blocks in place Operational excellence • Sole focus now on growing and optimising our Pathology and Agilex • Substantial value opportunity - sustaine
Slide 7: Healius Pathology – operating at scale
Healius Pathology – operating at scale 18m 7.6m 1978 30m pathology episodes unique Australians ACCs across the kms travelled by our annually1 served1 country2 courier cars1 37% 95% 87k 8,937 of Australian of metro Australia has unique referrers employees 3 hospitals serviced1 a Healius ACC within a
Slide 8: Industry fundamentals are strong
Industry fundamentals are strong Healthcare expenditure continues to grow Population is ageing, driving increasing demand for Pathology Australian healthcare expenditure – total ($ B, LHS) and per capita ($ ’000s, RHS)1 Australian population growth (# million) by age bracket Total healthcare expendi
Slide 9: Investment case for Healius
Investment case for Healius Strong tailwinds from macro trends Pathology is a critical component of the Australian health care system • Long-term growth of ~5% p.a. with consistent drivers – growing and ageing population, prevalence of chronic disease, benefits of additional tests 1 • Short-term slo
Slide 10: Delivering our Pathology Strategy
Delivering our Pathology Strategy 10 Healius Investor Day 2025
Slide 11: Our Pathology Strategy: profitability through lean growth
Our Pathology Strategy: profitability through lean growth Focused on providing better services for our patients and referrers to improve the volume and quality of the revenue we generate, and to become more efficient in our processes Customer Laboratory Emerging Enabled Digital People and service mo
Slide 12: Delivering our T27 plan: Significant milestones
Delivering our T27 plan Our goal is to deliver a high single digit EBIT margin in FY27 T27 Operating model change (Jul 24) High single digit % 1.5% We are here Jun 24 Jun 25 Jun 26 Jun 27 NUL funded Lumus sale Sale Digital program Stranded complete complete costs eliminated Significant milestones Cu
Slide 13: Simplified operating model
Simplified operating model We have successfully transitioned from four separate state-based businesses to a single national platform with operational and clinical leaders working together to deliver the best outcomes for patients and referrers Prior to July 2024 Current operating model – single plat
Slide 14: Three specific focus areas in each pillar
Three specific focus areas in each pillar Better network & Enhanced Growth in core Customer service 1 2 collections 3 customer business productivity experience Efficient & Logistics Reduced Laboratory 4 quality lab 5 6 consumable modernisation optimisation operations spend Veterinary Genomic Emergin
Slide 15: Customer Service
Customer Service Anthea Muir Group Executive Customer & Commercial 15
Slide 16: Customer Service programs of work
Customer Service Overall outcomes T27: Customer Service outcomes Customer We are here service Jun 24 Jun 25 Jun 26 Jun 27 Targeted GP & Specialist acquisition and retention Growth in core 1 business Revised pricing for non-MBS and private testing Improved revenue assurance Programs of work Network o
Slide 17: Strengthening our referrer value proposition
Customer Service 1 Growth in core business ✓ Delivered Strengthening our referrer value proposition ✓ In progress GP and Specialist centric processes and workflows – created in consultation with customers ✓ Strong CPD offering ✓ eReferral integration Clinical collaboration ✓ Digital CPD functionalit
Slide 18: Largest Pathology ACC network in Australia
Customer Service 2 Better network & collections productivity Largest Pathology ACC network in Australia Better aligning our network to market needs • Network size and spread (especially across Value based prioritisation of Regional & Rural) as a key value improvements in progress proposition to refe
Slide 19: Improving contact centre experience for referrers and patients
Customer Service 3 Enhanced customer experience Improving contact centre experience for referrers and patients Ongoing contact centre transformation has improved operational performance, enhancing our ability to serve our customers Providing a high-quality voice experience to our referrers and patie
Slide 20: Operations
Operations Arjun Narang Group Executive Operations 20 Healius Investor Day 2025
Slide 21: Laboratory Modernisation programs of work
Laboratory Modernisation Overall outcomes T27: Laboratory modernisation outcomes Laboratory We are here modernisation Jun 24 Jun 25 Jun 26 Jun 27 Digital & AI enabled Anatomical Pathology workflows Microbiology robotic automation Efficient & quality lab 4 operations Frontline-led process efficiency
Slide 22: Instrument Manager to enable national standardisation
Laboratory Modernisation 4 Efficient and quality lab operations Instrument Manager to enable national standardisation Priorities Measures / status Support volume consolidation for select tests into centres of excellence for scale economies Implementation in INSTRUMENT progress MANAGER (IM) Nationali
Slide 23: Instrument Manager rollout moving at pace
Laboratory Modernisation 4 Efficient and quality lab operations Instrument Manager rollout moving at pace Creating a common national infrastructure for all our metro and regional labs across the country Modern data management layer Creating immediate operational efficiencies One platform across all
Slide 24: Robotic automation for Microbiology
Laboratory Modernisation 4 Efficient and quality lab operations Robotic automation for Microbiology Priorities Measures / status Transition to liquid swabs simplifies collection and standardises sampling in the laboratory Planning in progress TRACK AUTOMATION Introduce fit for purpose automation Aut
Slide 25: Comprehensive program underway to reduce consumable spend
Laboratory Modernisation 6 Reduced consumable spend Comprehensive program underway to reduce consumable spend • Maximising operational life of existing assets • Enhancing vendor management and Supply • Lean process deployment strengthening vendor levers across operational areas to relationships mini
Slide 26: Emerging Diagnostics
Emerging Diagnostics Paul Anderson Chief Executive Officer & Managing Director Dr. Dora Papamakarios General Manager Genomic Diagnostics 26 Healius Investor Day 2025
Slide 27: Emerging Diagnostics programs of work
Emerging Diagnostics Overall outcomes T27: Emerging Diagnostics outcomes Emerging We are here Diagnostics Jun 24 Jun 25 Jun 26 Jun 27 Veterinary strategy refresh New Veterinary Pathology Go-to-market: customer propositions, marketing, scaling field sales teams Veterinary Pathology 7 & B2B Turnaround
Slide 28: Veterinary Pathology: growth driver for Healius
Emerging Diagnostics 7 Veterinary Pathology & B2B Veterinary Pathology: growth driver for Healius Australian Veterinary Pathology Market 1 Our ambition Deliver high growth within the companion animal sector, drive further efficiencies across the network and maximise partnerships in new and existing
Slide 29: Clinical trials offering bolstered through new modern platform
LaboratoryDiagnostics Emerging Modernisation 8 Clinical Trials Clinical trials offering bolstered through new modern platform Healius Pathology offers comprehensive laboratory services tailored to the unique needs of clinical trials across all phases (I-IV) Healius value proposition: • Broad Test Of
Slide 30: Genomic Diagnostics
Genomic Diagnostics Dr. Dora Papamakarios General Manager Genomic Diagnostics 30 Healius Investor Day 2025
Slide 31: Genomics progress has potential to radically improve patient outcomes
Emerging Diagnostics 9 Genomic Diagnostics Genomics progress has potential to radically improve patient outcomes Implications for Precision Medicine Personalised Medicine (e.g., Cancer Care) Genomics: the study of all of a person's genes (the • Tailored treatments genome), including interactions of
Slide 32: Genomics market is growing rapidly
Emerging Diagnostics 9 Genomic Diagnostics Genomics market is growing rapidly Australian Genomics Market1 CONTINUUM OF CARE CAGR 10% TARGETED DISEASE ~$2.0B RISK PREDICTION PERSONALISED MEDICINE DISEASE SCREENING DISEASE DIAGNOSIS DISEASE PROGNOSIS TREATMENTS MONITORING What’s my disease risk? Is my
Slide 33: Healius will leverage diagnostic innovation across 5 areas
Emerging Diagnostics 9 Genomic Diagnostics Healius will leverage diagnostic innovation across 5 areas Oncology Oncology Reproductive Health Haematology Personalised Germline Somatic Medicine Hereditary: Tumour: • Expanded Non-Invasive Prenatal • Expanded Haematological • Pharmacogenomic Testing (PGx
Slide 34: Healius well positioned to capture additional market share
Emerging Diagnostics 9 Genomic Diagnostics Healius well positioned to capture additional market share Strategic focus – executing our plan Revenue growth plans Annual revenue from Genomic Diagnostics Strategic planning and Revenue growth execution of 45% delivered in H1 FY25 Clinical and scientific
Slide 35: Technology Enablers
Technology Enablers Prasad Arav Group Executive Digital & Technology 35
Slide 36: Technology program is enabling transformation progress
Technology Enablers Program overview Technology program is enabling transformation progress • All technology investment geared towards enabling strategic outcomes, either: Medway suite of Customer Products – Driving revenue growth through improving customer service – Enabling efficiencies through au
Slide 37: Technology program - 8 specific areas of focus
Technology Enablers Program overview Technology program - 8 specific areas of focus Deep dive follows Legacy state prior New digital capability State of completion i. WEBSITES Outdated design on Modern, standard, digital front-door for new propositions e.g., Completed. Ongoing feature unsupported te
Slide 38: Collector Portal
Technology Enablers Case studies Collector Portal Customer service Priorities Measures Enable simpler, faster and paperless method of capturing patient information and test protocoling. COLLECTOR PORTAL Transform the workflow for patients Get collection guidance on containers, specimen volume, and h
Slide 39: Improving experience for appointment bookings
kimedway BB Deshboars © tnpre B vay book BE cancelations Request urgent pickup u © 2 hours 20 minutes est Reference Manus 39 | Healius Investor Day 2025 Dashboard e Q Patient lookup £3 Bookings (35) BOOKING 10 218916 443362 341474 263766 866877 383321 669362 745-800 8:00-8:30 820-845 9118-930 990-9.
Slide 40: Looking up patients to speed up service and reduce errors
timedway Patient lookup 9 R34Narangba Change location {cx} BB Deshboard ‘Scanned referral QR code © inpregeee Reaus BB vay book ADICB9 01/07/2024 By cancelators Last ee annex Date o i Smith F 12/05/1990 94) Mobile 0811 234 567 105 Wain Road, Toongabbie NSW 2146 Referting dacco ests requested De. Joh
Slide 41: Using AI to quickly protocol tests referred by doctors
, Al test matching complete The Al matched 7 tests from the freehand tests by the doctor. 41 | Healius Investor Day 2025 Using Al to quickly protocol tests referred by doctors
Slide 42: Automatically validating Medicare cards
timedw 85 Deshboard © iopre B vaydock By concelators ay ) @ Request urgent pickup © 2hours 20 Best Reerence Manuel 42 | Healius Investor Day 2025 © SMITH, Jane Request code | Request date Lab number AD1CB9 01/07/2024 Billing Type Medicare number Medicare 6459093819 Medicare number validated Proceed
Slide 43: Taking upfront payments for patient convenience
Payment Request code we) collection ste ovo7vz025 Patient name Jane Smith Amount (AUD) Ea 43 | Healius Investor Day 2025 Taking upfront payments for patient convenience
Slide 44: Providing specimen guidance to reduce errors
iF medway SMITH, Jane F 12/05/1990 (32) Bowes coteon ips ° B vaydock Tests BE Cancellations © FULL BLOOD EXAMINATION ada eoverad ® © HDL CHOLESTEROL, SERUM Nadia covered @ © VITAMIN B: ear Q Collection fee © Payable today Aso Specimen containers Collect epecimens lst below, ploace modify if necdes,
Slide 45: Supporting collectors with contextual reference manuals
Test reference Full Blood Examination Specimen container EDTA to Test information Panel code Specimen deserption Fac Blood Test frequecy sults available Daily Some day amt Absolto min: 0.5 mL Collection ecuirement Slides must be made AT TIME OF COLLECTION in the following reumstances: If difficulty
Slide 46: Digitisation of Anatomical Pathology workflows
Technology Enablers Case studies Laboratory Digitisation of Anatomical Pathology workflows Modernisation Priorities Measures Move to digital microscopy using scanned slides for select tissue types. DIGITAL PATHOLOGY Adopt digital slides and AI assisted Enable national case sharing and external repor
Slide 47: Having a single modern platform for laboratory staff
tipathway < Core Lab menu @reice.sers Lasorsrory SR: Select module i = B ® i . . i 47 | Heallus investor Day 2025 Having a single modern platform for laboratory staff | 1 |
Slide 48: Prioritising cases based on AI screening for Pathologists
tupathway < Core Lab menu Premises Lisorstony GA: a [ome] [ome] [ome } Eo [ome] 48 | Healius Investor Day 2025 Prioritising cases based on Al screening for Pathologists | ry |
Slide 49: Tagging slides with cancer identified for review
tipathway < Core Lab menu DERE ALO 8 d co [cares ea [owes co Lmcs a ae [ewes ca [cen } oo [ewes 49 | Healius Investor Day 2025 Tagging slides with cancer identified for review | | |
Slide 50: Showing AI powered heatmaps of cancer likelihood
tipathway HEIDELBERG LABORATORY Pa] t Heatmaps Prostate Adenocarcinoma @ Keown Other Cancer Slide-level Gleagon Score Number of Cores ; . . . 1 50 | Healius Investor Day 2025 Showing Al powered heatmaps of cancer likelihood | | |
Slide 51: Automatically zooming into points of interest
tipathway HEIDELBERG LABORATORY a] t 51 | Healius Investor Day 2025 Automatically zooming into review cancer points of interest | 1 |
Slide 52: Helping with much faster and more accurate measurements
tipathway HEIDELBERG LABORATORY 8 t tmape D st Total Tumor Length rm) Tissue Length of Most Taat_ 00mm | =m 0 sme ; 7 . | 52 | Healius Investor Day 2025 Helping with much faster and more accurate measurements | 1 |
Slide 53: Providing easy access to patient history
tipathway ¢ Corelab/ 25-123141254/ DOR {9 bury Hitology Department estes . | 53 | Healius Investor Day 2025 Providing easy access to patient history to inform clinical decisions | 1 |
Slide 54: Real-time laboratory dashboards to manage efficiency
Healius Investor Day 2025 Real-time laboratory dashboards to manage efficiency
Slide 55: Doctor Portal
Technology Enablers Case studies Doctor Portal Customer service Priorities Measures Improve report visualisation e.g. tabulated results, cumulative data charting, synoptic summaries etc DOCTOR PORTAL Real-time results for Specialists and GPs. Improve diagnostic decision Allow custom analysis of biom
Slide 56: Easier for referrers to review test results
56 | Healius Investor Day 2025 My results ‘Auto refresh every 15 mins (Ponarnime ~) (emoearon ~)| QD PATIENT NAME Dianne Russel Ronald Richards Darlene Robertson Leslie Alexander Darrell Steward Devon Lane Annette Black Courtney Henry Kriotin v/atoon Tost, Patient 10/10/1960 20/06/1988 02/07/1971 4/
Slide 57: Enhancing reports with clinical decision insights
€ Report detail sl Alllocations {rs} e DREAIL, Sarah 92/1970 (549) | F | +61 401090909 | emall@emaiicomau Labno 24-57856874 Celected 27 Dee 2024 08:21 AM AEST Status Report ready 4 28 Dec 2024 12:01 PM AEST Test Index B Pathology report summary & clinical guidance Reported (2) ‘* Peripheral Blood Sm
Slide 58: Clinical queries and pathology report summary
58 | Healius Investor Day 2025 € Report detail DREAIL, Sarah Labno, 24-57856874 Status Pattially reported Test index Roported (2) roe Jeure Pending (4) IRON STUDIES up sTuotes VITAMIN D THYROID PROFILE + Addtect ) Collected 28 Jul 2024 08:21 AM AEST sstveported 28 Jul 2024 12:01 PM AEST A. Critical:
Slide 59: Enabling biomarker dashboards relevant to Specialist referrers
59 | Healius Investor Day 2025 Patient profile 0s) DREAIL, Sarah F | 461407090909 | emaliemaiicomau Key biometrics (atest recut 22/08/2024) a attcaions (feo beod> Haemoglobin WBC count RBC count Platelets 82a ors 6.0.20 AA vous a0 Blood Glucose Vitamin D Report history 1 (Wiman | ( FOLATE senuM [ RO
Slide 60: Trend analysis leveraging historical patient data
Custom analysis All locations {rs} 0s] DREAIL, Sarah p2r02r1870 (S49) | F | +61401090908 | emaiemai.comau climea croup ~ ] ( @ Lastmonths ~ ) | ( Aad annotation HEME - Complete Blood Count Lamatuetes , ; ‘ wee : J 60 | Healius Investor Day 2025 Trend analysis leveraging historical patient data | rT
Slide 61: Supporting self-service for report sharing
Send report Select provider 58657476 Ralph Edwords 18 Smith Street, Chatswood NSW 2067 44575364 Darrell Steward Suite 12/405 Laurel Street, Chatswood 48649522 Courtney Henry 5221675F — Marvin Mckinney 9 Third St, Ashbury NSW 2193 Select method Sond to my PMS send via Fac @ Reason for send (optional)
Slide 62: Helping GPs with Continuing Professional Development (CPD)
CPD & Education 1 attcaions @ Reports are being processed soon Please check your location, college and CPD number details are upto date in your settings page- please contact the CPD team with any updates. Dr Fiona Wilson Total audits submitted this year 20 Cenificates }(avats }[ Learning centre | {
Slide 63: Providing an online platform for Medical Practice services
tthealius Vaccines Jeson white » ( Ca @ % Vaccines nerarmisa Your order FR concumasies : Avoxim® ue PD Couns Hovrix@ 1440 ce Avaxim® $510.00 B eferay 2309 Havtie® Junior « Engerin@8 Adult $256.20 Yoatad Adult EB myowcers 093 B5 Company orders © cw Yagia® Paed a $766.20 $0.00 Shopping lists Neparmise
Slide 64: Steve McIntyre
Steve McIntyre Chief Executive Officer 64
Slide 65: Agilex supports Phase 1 trials in Australia from across the globe
Agilex supports Phase 1 trials in Australia from across the globe Market leading bioanalytical laboratory • Full-service, best-in-class provider with broad capabilities across bespoke assay development, pharmacokinetics, pharmacodynamics and toxicology • Leading bioanalytical laboratory in APAC with
Slide 66: Agilex is poised for growth
Agilex is poised for growth Including through joint market propositions / synergies with Healius Pathology • Capital investment in laboratory equipment and toxicology capability • Expanded Adelaide lab and completed Brisbane toxicology facility works (now fully operational) Strengthened • Robotics i
Slide 67: Financial Update
Financial Update Steve Humphries Chief Financial Officer 67 Healius Investor Day 2025
Slide 68: Financial Management
Financial Management Financial Management & EBIT margins (Pathology only business post Lumus sale) • High single digit margin target by June 2027 announced ⁃ Revenue growth supported by improved customer service proposition, plus o Volumes and GP attendances returning to long term trends (plus new G
Slide 69: Cost Management
Cost Management Overall cost base Cost Management & EBIT margins The major cost components are: • Labour costs (1H25 49.5%) ⁃ Comprise circa half of overall cost base and therefore many efficiency opportunities Labour 49.5% o Improvement through workforce optimisation key (workforce management - ope
Slide 70: Trading & Capital Management
Trading & Capital Management Trading update Capital management • Volumes up 4.0% Feb 2025 year to date • The company intends to pay a Special Dividend of approx. $300m (subject to Lumus sale completion) • Revenue up 6.2% Feb 2025 year to date ⁃ 41.3 cents per share fully franked ⁃ franking credit of
Slide 71: Summary & Questions
Summary & Questions
Slide 72: Thank you
Thank you